TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15617954

Group type: EXPERIMENTAL
Intervention: Troglitazone 150 mg/d
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Troglitazone 300 mg/d
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Troglitazone 600 mg/d
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study: 11292472

Group type: EXPERIMENTAL
Intervention: Media campaign to increase knowledge about emergency contraception
Number of subjects: 0
Study: 9239526

Group type: EXPERIMENTAL
Intervention: Paclitaxel therapy at a dose of 175 mg/m2
Number of subjects: 23

Group type: COMPARATOR
Intervention: Pretreatment with potentially neurotoxic drugs (cisplatin and carboplatin)
Number of subjects: 23
Study: 8108224

Group type: EXPERIMENTAL
Intervention: HbOC-DTP combined vaccine
Number of subjects: 6644

Group type: COMPARATOR
Intervention: Separate injections of HbOC and DTP vaccines
Number of subjects: 6644
Study: 2888477

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 0
Study: 31385552

Group type: EXPERIMENTAL
Intervention: VOT manipulation (voice onset time) in two-word sequences with matching and mismatching VOTs.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mouse movement trajectories recorded during the task.
Number of subjects: 20
Study: 29538179

Group type: EXPERIMENTAL
Intervention: Intravenous iron supplementation (ferric carboxymaltose)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation (ferrous sulfate)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 28718081

Group type: EXPERIMENTAL
Intervention: Sage one‐step medium (Origio)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Continuous Single Culture (CSC) medium (Irvine Scientific)
Number of subjects: 33
Study: 26428942

Group type: EXPERIMENTAL
Intervention: 4 courses of cisplatin 100 mg/mq and paclitaxel 175 mg/mq every 21 days (Group A)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 6 courses of cisplatin 100 mg/mq and paclitaxel 175 mg/mq every 21 days (Group B)
Number of subjects: 200
Study: 23229241

Group type: EXPERIMENTAL
Intervention: 8% Arginine-CaCO₃
Number of subjects: 36

Group type: COMPARATOR
Intervention: 1.23% NaF-gel
Number of subjects: 36
Study: 21046229

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 100
Study: 18261787

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 17345811

Group type: EXPERIMENTAL
Intervention: Acrylic hydrophobic foldable intraocular lens with rigid haptics
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Acrylic hydrophobic foldable intraocular lens with pliable haptics
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 1-piece acrylic hydrophobic IOL with soft acrylic loops
Number of subjects: 108
Study: 14662662

Group type: EXPERIMENTAL
Intervention: Artichoke extract (3 capsules)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (indistinguishable inert capsules)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Artichoke extract
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 11058673

Group type: EXPERIMENTAL
Intervention: Levomethadyl acetate (75 to 115 mg)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Buprenorphine (16 to 32 mg)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: High-dose methadone (60 to 100 mg)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Low-dose methadone (20 mg)
Number of subjects: 220
Study: 8967840

Group type: EXPERIMENTAL
Intervention: Adrenergic vegetative neural terminals (VNT) involvement in stroma formation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunocompetent cells involvement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VNT of the adrenergic part
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stroma formation in fibroadenoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autonomization of stroma formation
Number of subjects: 0
Study: 1621669

Group type: EXPERIMENTAL
Intervention: 10 mg/kg ibuprofen therapy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 15 mg/kg acetaminophen therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: 2.5 mg/kg ibuprofen therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: 5 mg/kg ibuprofen therapy
Number of subjects: 64
Study: 6487947

Group type: EXPERIMENTAL
Intervention: Small dose of alcohol (0.44 ml.kg‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol (0.88 ml.kg‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0.0 ml.kg‐1)
Number of subjects: 12
Study: 29769080

Group type: EXPERIMENTAL
Intervention: Hispanic Kidney Transplant Program (HKTP)
Number of subjects: 2
Study: 26751765

Group type: EXPERIMENTAL
Intervention: Inactivated Enterovirus 71 vaccine
Number of subjects: 0
Study: 24929936

Group type: EXPERIMENTAL
Intervention: Intensive treatment (4 sessions of 1 hour per week for 2 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard treatment (1 session of 1 hour per week for 8 weeks)
Number of subjects: 16
Study: 23585666

Group type: EXPERIMENTAL
Intervention: L-T3 (liothyronine)
Number of subjects: 13

Group type: COMPARATOR
Intervention: L-T4 (levothyroxine)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 5 μg TRH dose
Number of subjects: 13
Study: 20937051

Group type: EXPERIMENTAL
Intervention: Furosemide IV infusion + oral midodrine 15 mg administered 30 min before furosemide
Number of subjects: 15

Group type: COMPARATOR
Intervention: Furosemide IV infusion + oral placebo administered 30 min before furosemide
Number of subjects: 15
Study: 18384418

Group type: EXPERIMENTAL
Intervention: 0.5 microg kg(‐1) min(‐1) glyceryl trinitrate (GTN) infusion over 20 min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 8
Study: 16730418

Group type: EXPERIMENTAL
Intervention: +ISO (soy protein with 83 mg isoflavones)
Number of subjects: 145

Group type: COMPARATOR
Intervention: ‐ISO (soy protein with 3 mg isoflavones)
Number of subjects: 145
Study: 14680611

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA), 500 mg/day for 5 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mifepristone (MIF), 100 mg/day for 5 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mifepristone (MIF) + Medroxyprogesterone acetate (MPA), 100 mg/day + 500 mg/day for 5 days
Number of subjects: 30
Study: 10875882

Group type: EXPERIMENTAL
Intervention: Serum inhibin A
Number of subjects: 1496

Group type: EXPERIMENTAL
Intervention: Serum activin A
Number of subjects: 1496

Group type: COMPARATOR
Intervention: Screening efficacy
Number of subjects: 1496
Study: 9537154

Group type: EXPERIMENTAL
Intervention: Pelli-Robson chart
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cambridge gratings
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Regan chart
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: UW chart
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Vistech chart
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: All charts
Number of subjects: 39
Study: 1440105

Group type: EXPERIMENTAL
Intervention: Systematic training in performing case management activities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ordinary services provided by the hospital social work department
Number of subjects: 0
Study: 2428269

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (10 ml/kg body weight)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 5.5% oxypolygelatin (10 ml/kg body weight)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 5.0% human albumin (10 ml/kg body weight)
Number of subjects: 28
Study: 30282699

Group type: EXPERIMENTAL
Intervention: Gastric banding
Number of subjects: 88

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 88
Study: 26332311

Group type: EXPERIMENTAL
Intervention: In-service educational session on IBD health maintenance
Number of subjects: 50
Study: 24629060

Group type: EXPERIMENTAL
Intervention: Dysport (60 units)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ISDN (10 mg/ml, 1%)
Number of subjects: 60
Study: 22849754

Group type: EXPERIMENTAL
Intervention: Mailed Questionnaire (MQ)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Computer-Assisted Telephone Interview (CATI)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Mailed Questionnaire (MQ) for fathers
Number of subjects: 392

Group type: COMPARATOR
Intervention: Computer-Assisted Telephone Interview (CATI) for fathers
Number of subjects: 392
Study: 20579405

Group type: EXPERIMENTAL
Intervention: Low-fat dairy consumption (500 ml low-fat milk and 150 g low-fat yogurt)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Carbohydrate-rich control products (600 ml fruit juice and three fruit biscuits)
Number of subjects: 35
Study: 18019902

Group type: EXPERIMENTAL
Intervention: Wireless Palm‐based electronic prescribing system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Workarounds to create acceptable prescribing processes
Number of subjects: 0
Study: 16182039

Group type: EXPERIMENTAL
Intervention: 3-month oral controlled diet followed by 3-month spontaneous dietary intake
Number of subjects: 90

Group type: COMPARATOR
Intervention: 3-month spontaneous dietary intake followed by 3-month controlled diet
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups during controlled diet
Number of subjects: 90
Study: 11205423

Group type: EXPERIMENTAL
Intervention: Inhaler
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Patch
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Gum
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Nasal Spray
Number of subjects: 504

Group type: COMPARATOR
Intervention: Control (Preferred Product)
Number of subjects: 504
Study: 9032190

Group type: EXPERIMENTAL
Intervention: 60% O2
Number of subjects: 11

Group type: COMPARATOR
Intervention: Room air (RA)
Number of subjects: 11
Study: 7904330

Group type: EXPERIMENTAL
Intervention: Micronized progesterone (1,200 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High levels of allopregnanolone and pregnanolone (> or = 95.55 nmol/l)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 18
Study: 3030904

Group type: EXPERIMENTAL
Intervention: Bran biscuits (12 biscuits, 1 = 1.3 g fibre)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo biscuits (12 biscuits, 1 = 0.23 g fibre)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bran biscuits
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo biscuits
Number of subjects: 28
Study: 30569827

Group type: EXPERIMENTAL
Intervention: Preschool PATHS curriculum
Number of subjects: 5
Study: 27336206

Group type: EXPERIMENTAL
Intervention: Intensive weight loss intervention (IWL) consisting of 12 weeks of very-low-energy diet (800 kcal/day) + 4 weeks of low-calorie conventional food-based diet (CFD) to promote 15% weight loss.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard-of-care nutrition counseling (SCN) consisting of 16 weeks of CFD to promote ≥5% weight loss.
Number of subjects: 14
Study: 23039030

Group type: EXPERIMENTAL
Intervention: abacavir/lamivudine + atazanavir/ritonavir
Number of subjects: 515
Study: 21142812

Group type: EXPERIMENTAL
Intervention: Losartan/HCTZ (50mg/12.5mg daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Losartan (50mg/day)
Number of subjects: 29
Study: 18262712

Group type: EXPERIMENTAL
Intervention: PCPT biopsy policy
Number of subjects: 15773

Group type: COMPARATOR
Intervention: Screening in ERSPC
Number of subjects: 15773
Study: 16502143

Group type: EXPERIMENTAL
Intervention: Slick Tracy Home Team Program (intervention group)
Number of subjects: 3623

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3623
Study: 12953850

Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril 4 mg daily, with optional indapamide)
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril plus indapamide)
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: Single-drug therapy (perindopril alone)
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 6105
Study: 10703679

Group type: COMPARATOR
Intervention: Hypertonic saline [3%]
Number of subjects: 9

Group type: COMPARATOR
Intervention: Albumin [20%]
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch (HES) [10%]
Number of subjects: 9
Study: 9052518

Group type: EXPERIMENTAL
Intervention: Lactose feeding for 10 days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dextrose feeding for 10 days
Number of subjects: 6
Study: 7870914

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Instructions (told caffeine, told no caffeine, not told)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instructions (told caffeine)
Number of subjects: 0
Study: 3039882

Group type: EXPERIMENTAL
Intervention: Acyclovir, 5 mg/kg intravenously every 8 hours
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no acyclovir)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 30083910

Group type: EXPERIMENTAL
Intervention: MyoVision lenses
Number of subjects: 207

Group type: COMPARATOR
Intervention: Single vision lenses (SVLs)
Number of subjects: 207
Study: 27039799

Group type: EXPERIMENTAL
Intervention: R-CHOP-14
Number of subjects: 143

Group type: COMPARATOR
Intervention: R-CHOP-21
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: R-CHOP-14 and R-CHOP-21
Number of subjects: 143
Study: 25372219

Group type: EXPERIMENTAL
Intervention: Low intensity laser therapy (LILT) - 790 nm, 30 mW continuous wave, 0.13 cm2 focal spot, applied energy of 3.6 J, fluence of 27.69 J/cm2
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 20% benzocaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pressure
Number of subjects: 80

Group type: COMPARATOR
Intervention: Light touch
Number of subjects: 80
Study: 23457689

Group type: EXPERIMENTAL
Intervention: Bedtime restriction and basic sleep hygiene
Number of subjects: 45

Group type: COMPARATOR
Intervention: Basic sleep hygiene only
Number of subjects: 45
Study: 19863517

Group type: EXPERIMENTAL
Intervention: 400 mg PTX‐SR (Apo‐Pentoxifylline, Apotex Inc.) twice daily for 6 months
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo, similar regimen for 6 months
Number of subjects: 228
Study: 17666447

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Etanercept and methotrexate (ETN+MTX)
Number of subjects: 315
Study: 20406961

Group type: EXPERIMENTAL
Intervention: Dense breast tissue (pattern IV or V)
Number of subjects: 15658

Group type: COMPARATOR
Intervention: Nondense breast tissue
Number of subjects: 15658
Study: 16537301

Group type: EXPERIMENTAL
Intervention: Simulated vaginal microbicide
Number of subjects: 96
Study: 12269974

Group type: EXPERIMENTAL
Intervention: Indoramin 25 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propranolol 80 mg
Number of subjects: 10
Study: 9727511

Group type: EXPERIMENTAL
Intervention: Diode laser trabeculoplasty (DLT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 46
Study: 8067273

Group type: EXPERIMENTAL
Intervention: Bright light therapy (mean 4106 lx)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Dim light therapy (mean 96 lx)
Number of subjects: 43
Study: 3197677

Group type: EXPERIMENTAL
Intervention: Neurotol slow (slow-release carbamazepine), administered twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tegretol (conventional carbamazepine), administered three times daily
Number of subjects: 20
Study: 29574518

Group type: EXPERIMENTAL
Intervention: Minodronate (MIN) 50 mg once-monthly
Number of subjects: 83

Group type: COMPARATOR
Intervention: Risedronate (RIS) 75 mg once-monthly
Number of subjects: 83
Study: 26781865

Group type: EXPERIMENTAL
Intervention: Announced tenofovir levels
Number of subjects: 268

Group type: COMPARATOR
Intervention: Unannounced tenofovir levels
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Announced tenofovir levels in Kabwohe
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Announced tenofovir levels in Kampala
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Announced tenofovir levels in Tororo
Number of subjects: 268
Study: 26528934

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA) or bipolar prosthesis using MIS transgluteal approach
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional surgical approach (control group)
Number of subjects: 40
Study: 23247719

Group type: EXPERIMENTAL
Intervention: Mailed survey invitation through cancer registry
Number of subjects: 505
Study: 20544611

Group type: EXPERIMENTAL
Intervention: Training group (TG, n = 32)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 48
Study: 18356403

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILS) with weight loss of 3-7% body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILS) with weight loss of >7% body weight
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weight loss <3% body weight
Number of subjects: 0
Study: 16641239

Group type: EXPERIMENTAL
Intervention: Working memory for conjunctions at 8 s delays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Working memory for objects and locations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hippocampus involvement in conjunction working memory
Number of subjects: 0
Study: 14623651

Group type: COMPARATOR
Intervention: Conventional magnetic resonance imaging
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intravenous contrast-enhanced indirect magnetic resonance arthrography
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intraarticular contrast-enhanced direct magnetic resonance arthrography
Number of subjects: 41
Study: 10783839

Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse (Listerine Antiseptic)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sterile saline negative control
Number of subjects: 17
Study: 8894333

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 16
Study: 2056262

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 6605082

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 78

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Medical treatment and Surgical treatment
Number of subjects: 78
Study: 29494458

Group type: EXPERIMENTAL
Intervention: Derotation connectors (D+ group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: No derotation connectors (D- group)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study: 26964825

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) at 125 mm Hg
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) at 75 mm Hg
Number of subjects: 580

Group type: COMPARATOR
Intervention: Traditional treatment (leaving wounds open)
Number of subjects: 580
Study: 23958073

Group type: EXPERIMENTAL
Intervention: EZ-Blocker
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cohen Flex-Tip blocker
Number of subjects: 40
Study: 22592556

Group type: EXPERIMENTAL
Intervention: Acupuncture (AP) at ST36
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham-AP
Number of subjects: 20

Group type: COMPARATOR
Intervention: No-AP
Number of subjects: 20
Study: 21250566

Group type: EXPERIMENTAL
Intervention: CPP-ACP containing cream applied for 3 minutes once per day during a 3-week treatment period
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard fluoride toothpaste (1450 ppm F- as NaF) and abstaining from other oral hygiene products
Number of subjects: 32
Study: 18411019

Group type: EXPERIMENTAL
Intervention: Palliative care
Number of subjects: 149

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 149
Study: 15781506

Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil (bolus doses of propofol 3-5 mg/kg and remifentanil 1-4 microg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Propofol with sevoflurane and nitrous oxide (propofol 3-5 mg/kg with 2%-8% sevoflurane and 70% nitrous oxide)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil
Number of subjects: 21
Study: 15175435

Group type: EXPERIMENTAL
Intervention: IFL plus bevacizumab (5 mg/kg every two weeks)
Number of subjects: 813

Group type: COMPARATOR
Intervention: IFL plus placebo
Number of subjects: 813
Study: 11753186

Group type: EXPERIMENTAL
Intervention: Gentamicin plus clindamycin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gentamicin plus penicillin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gentamicin plus clindamycin or gentamicin plus penicillin
Number of subjects: 18
Study: 9305487

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg once daily
Number of subjects: 424

Group type: COMPARATOR
Intervention: Cisapride 10 mg four times daily
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Omeprazole (both doses)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 424

Group type: COMPARATOR
Intervention: Omeprazole vs Cisapride
Number of subjects: 424
Study: 8351172

Group type: EXPERIMENTAL
Intervention: Rush rods
Number of subjects: 50

Group type: COMPARATOR
Intervention: AO plates
Number of subjects: 50
Study: 3538987

Group type: EXPERIMENTAL
Intervention: sublingual buprenorphine 200 mcg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: sublingual buprenorphine 400 mcg
Number of subjects: 288

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 288
Study: 29471124

Group type: EXPERIMENTAL
Intervention: Daily vitamin D3 supplementation (400, 4000, or 10,000 IU)
Number of subjects: 0